<p><strong>贊助有助於擴展經過驗證的 Alpha-1 檢測策略，從而實現更早的患者識別</strong></p>
<p>, /PRNewswire/ -- AlphaDetect 是一個由 Alpha-1 基金會支持和資助的非營利組織，今天宣佈賽諾菲作為其首批行業贊助商之一。這一支持進一步加強了加速常規檢測 Alpha-1 抗胰蛋白酶缺乏症（Alpha-1）的努力，與臨牀實踐指南一致。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.jpg"/></p>
<p>AlphaDetect 致力於通過提升意識、消除障礙和擴大臨牀實踐指南中檢測建議的採用，識別所有面臨這種漸進性遺傳疾病風險的人，以便 Alpha-1 檢測成為受肺部和肝臟疾病影響患者的常規做法。該組織正在增加 Alpha-1 檢測工具和支持在實踐層面的可用性，同時與醫療服務提供者合作，戰略性地推進醫療系統中的協議和技術。</p>
<p>&#34;賽諾菲很自豪能夠支持 AlphaDetect 的使命，作為首批贊助商之一，增加和加速 Alpha-1 檢測，&#34; 賽諾菲罕見疾病全球醫學事務負責人 Alaa Hamed 説。&#34;這一努力代表了在揭示那些面臨這種極度未被診斷的罕見疾病風險的人的重要一步，這種疾病可能會產生毀滅性的影響。這一合作反映了我們對 Alpha-1 社區的承諾，特別是在推動意識和認可方面。確保患有這種潛在遺傳疾病的人能夠在其護理旅程中更早地發現這一診斷，對他們獲得更好結果的機會至關重要。我們期待與 AlphaDetect 在這一重要努力中合作。&#34;</p>
<p>&#34;Alpha-1 是一種漸進性遺傳性肺部和肝臟疾病，檢測延遲可能會產生真實且不可逆轉的後果，&#34; AlphaDetect 首席執行官 Julie Murray 説。&#34;快速和系統地擴大識別高風險患者的有效方法，可以為受影響者提供及時的決策信息。賽諾菲的支持和承諾是重要且令人感激的，因為我們繼續推進 Alpha-1 檢測。&#34;</p>
<p>Alpha-1 仍然顯著未被診斷，估計超過 90% 的受影響個體尚未被識別。它也是已知的慢性阻塞性肺病（COPD）的主要遺傳風險因素，並與兒童和成人的肝病相關。重要的是，檢測還提供了進入 Alpha-1 社區的切入點，為未來的旅程打開了獲取全面信息、支持和資源的大門。</p>
<p>&#34;這一支持建立在賽諾菲對罕見疾病和 Alpha-1 社區的承諾之上，&#34; Alpha-1 基金會首席執行官 Scott Santarella 説。&#34;這也代表了我們在檢測方法上向前邁出的重要一步。通過通過 AlphaDetect 擴大這些努力，我們可以更早地識別更多個體，並實現 Alpha-1 基金會改善他們生活的使命。&#34;</p>
<p>最新的臨牀指南建議對所有患有 COPD、治療抵抗性哮喘或原因不明的肝病的個體進行 Alpha-1 檢測。然而，現實世界的結果遠遠低於這一標準。AlphaDetect 致力於縮小這一差距。賽諾菲的贊助和承諾將幫助 AlphaDetect 擴大提供者教育、拓寬檢測策略，並在 Alpha-1 社區內合作，識別患有 Alpha-1 的個體。</p>
<p><strong>關於 AlphaDetect</strong></p>
<p>AlphaDetect 成立於 2025 年，加速檢測以揭示所有在遺傳上面臨 Alpha-1 風險的人。AlphaDetect 位於北卡羅來納州達勒姆，將作為有限責任公司和 Alpha-1 基金會的非營利子公司運營，享有根據《國內税收法》第 501(c) 3 條款的免税地位。</p>
<p>欲瞭解更多信息，請訪問 https://alpha1.org/alphadetect/</p>
<p>聯繫人：Cindy Machles</p>
<p>cmachles@alphadetect.org</p>
<p><strong>關於賽諾菲</strong></p>
<p>賽諾菲是一家以研發為驅動、以人工智能為動力的生物製藥公司，致力於改善人們的生活並實現可持續增長。我們運用對免疫系統的深刻理解，發明治療和保護全球數百萬人的藥物和疫苗，擁有一條創新的產品管線，可能使更多人受益。我們的團隊以一個目標為指導：追求科學的奇蹟以改善人們的生活；這激勵我們推動進步，為我們服務的人民和社區帶來積極影響，解決我們時代最緊迫的醫療、環境和社會挑戰。賽諾菲在 EURONEXT: SAN 和 NASDAQ: SNY 上市。</p>
<p>欲瞭解更多信息，請訪問 www.sanofi.com</p>
<p>聯繫人：Evan Berland</p>
<p>evan.berland@sanofi.com</p>
<p><strong>關於 Alpha-1 基金會</strong></p>
<p>Alpha-1 基金會成立於 1995 年，致力於尋找 Alpha-1 抗胰蛋白酶缺乏症（Alpha-1）的治癒，並改善全球受該疾病影響的人的生活。A1F 已投資超過 1 億美元支持北美、歐洲、中東和澳大利亞 130 個機構的 Alpha-1 研究和項目。</p>
<p>欲瞭解更多信息，請訪問 alpha1.org</p>
<p>聯繫人：Jeanne Kushner</p>
<p>jkushner@alpha1.org</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973907/Sanofi.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973907/Sanofi.jpg"/></p>
<p>來源：Alpha-1 基金會</p>

賽諾菲

賽諾菲集團

<p>賽諾菲已成為 AlphaDetect 的首批贊助商，該組織是一家專注於加速阿爾法-1 抗胰蛋白酶缺乏症（Alpha-1）檢測的非營利組織。此次合作旨在提高對這一被低估的遺傳疾病的認識和檢測，該疾病對肺部和肝臟健康有顯著影響。賽諾菲的支持將有助於擴展檢測策略，並通過確保早期診斷來改善患者的治療結果。Alpha-1 仍然在很大程度上未被診斷，超過 90% 的受影響個體尚未被識別。這一合作反映了賽諾菲對 Alpha-1 社區和罕見疾病倡議的承諾</p>

<p><strong>The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification</strong></p>
<div class="lb-trans"><p><strong>贊助有助於擴展經過驗證的 Alpha-1 檢測策略，從而實現更早的患者識別</strong></p>
</div><p>, /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation, today announced Sanofi as one of its inaugural industry sponsors. This support further strengthens efforts to accelerate routine detection of Alpha-1 Antitrypsin Deficiency (Alpha-1), consistent with clinical practice guidelines.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- AlphaDetect 是一個由 Alpha-1 基金會支持和資助的非營利組織，今天宣佈賽諾菲作為其首批行業贊助商之一。這一支持進一步加強了加速常規檢測 Alpha-1 抗胰蛋白酶缺乏症（Alpha-1）的努力，與臨牀實踐指南一致。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.jpg"/></p>
<p>AlphaDetect is dedicated to identifying everyone at risk for this progressive, genetic condition by elevating awareness, removing barriers, and expanding adoption of testing recommendations in clinical practice guidelines, so that Alpha-1 detection becomes routine for patients impacted by lung and liver disease. The organization is increasing the availability of Alpha-1 detection tools and support at the practice level while partnering with healthcare providers to strategically advance protocols and technologies across healthcare systems.</p>
<div class="lb-trans"><p>AlphaDetect 致力於通過提升意識、消除障礙和擴大臨牀實踐指南中檢測建議的採用，識別所有面臨這種漸進性遺傳疾病風險的人，以便 Alpha-1 檢測成為受肺部和肝臟疾病影響患者的常規做法。該組織正在增加 Alpha-1 檢測工具和支持在實踐層面的可用性，同時與醫療服務提供者合作，戰略性地推進醫療系統中的協議和技術。</p>
</div><p>&#34;Sanofi is proud to support AlphaDetect's mission, as one of the inaugural sponsors, to increase and accelerate Alpha-1 detection,&#34; said Alaa Hamed, Global Head of Medical Affairs, Rare Diseases at Sanofi. &#34;This effort represents a meaningful step forward in uncovering those at risk for this extremely underdiagnosed rare disease, which can have a devastating impact. This collaboration reflects our commitment to the Alpha-1 community, particularly in driving awareness and recognition. Ensuring that people who have this underlying genetic condition can uncover this diagnosis earlier in their care journey is fundamental to their chance of better outcomes. We look forward to working with AlphaDetect on this important effort.&#34;</p>
<div class="lb-trans"><p>&#34;賽諾菲很自豪能夠支持 AlphaDetect 的使命，作為首批贊助商之一，增加和加速 Alpha-1 檢測，&#34; 賽諾菲罕見疾病全球醫學事務負責人 Alaa Hamed 説。&#34;這一努力代表了在揭示那些面臨這種極度未被診斷的罕見疾病風險的人的重要一步，這種疾病可能會產生毀滅性的影響。這一合作反映了我們對 Alpha-1 社區的承諾，特別是在推動意識和認可方面。確保患有這種潛在遺傳疾病的人能夠在其護理旅程中更早地發現這一診斷，對他們獲得更好結果的機會至關重要。我們期待與 AlphaDetect 在這一重要努力中合作。&#34;</p>
</div><p>&#34;Alpha-1 is a progressive, genetic lung and liver condition where delays in detection may have real, irreversible consequences, &#34; said Julie Murray, CEO of AlphaDetect. &#34;The ability to scale proven approaches to identifying at-risk patients, quickly and systematically, can inform timely decisions for those impacted. The support and commitment from Sanofi are important and appreciated as we continue to advance Alpha-1 detection.&#34;</p>
<div class="lb-trans"><p>&#34;Alpha-1 是一種漸進性遺傳性肺部和肝臟疾病，檢測延遲可能會產生真實且不可逆轉的後果，&#34; AlphaDetect 首席執行官 Julie Murray 説。&#34;快速和系統地擴大識別高風險患者的有效方法，可以為受影響者提供及時的決策信息。賽諾菲的支持和承諾是重要且令人感激的，因為我們繼續推進 Alpha-1 檢測。&#34;</p>
</div><p>Alpha-1 remains significantly underdiagnosed, with more than 90% of affected individuals estimated to be unidentified. It is also the leading known genetic risk factor for COPD and is associated with liver disease in both children and adults. Importantly, detection also provides a point of entry into the Alpha-1 community, opening the door to the comprehensive information, support, and resources needed for the journey ahead.</p>
<div class="lb-trans"><p>Alpha-1 仍然顯著未被診斷，估計超過 90% 的受影響個體尚未被識別。它也是已知的慢性阻塞性肺病（COPD）的主要遺傳風險因素，並與兒童和成人的肝病相關。重要的是，檢測還提供了進入 Alpha-1 社區的切入點，為未來的旅程打開了獲取全面信息、支持和資源的大門。</p>
</div><p>&#34;This support builds on Sanofi's commitment to rare disease and the Alpha-1 community,&#34; said Scott Santarella, CEO of the Alpha-1 Foundation. &#34;It also represents an important step forward in how we approach detection. By expanding these efforts through AlphaDetect, we can identify more individuals earlier and deliver on the Alpha-1 Foundation's mission of improving their lives.&#34;</p>
<div class="lb-trans"><p>&#34;這一支持建立在賽諾菲對罕見疾病和 Alpha-1 社區的承諾之上，&#34; Alpha-1 基金會首席執行官 Scott Santarella 説。&#34;這也代表了我們在檢測方法上向前邁出的重要一步。通過通過 AlphaDetect 擴大這些努力，我們可以更早地識別更多個體，並實現 Alpha-1 基金會改善他們生活的使命。&#34;</p>
</div><p>The latest clinical guidelines recommend testing for Alpha-1 in all individuals with COPD, treatment-resistant asthma, or unexplained liver disease. Yet real-world results fall far short of this. AlphaDetect is committed to closing the gap. Sanofi's sponsorship and commitment will help AlphaDetect scale efforts to enhance provider education, broaden detection strategies, and work across the Alpha-1 community to identify individuals with Alpha-1.</p>
<div class="lb-trans"><p>最新的臨牀指南建議對所有患有 COPD、治療抵抗性哮喘或原因不明的肝病的個體進行 Alpha-1 檢測。然而，現實世界的結果遠遠低於這一標準。AlphaDetect 致力於縮小這一差距。賽諾菲的贊助和承諾將幫助 AlphaDetect 擴大提供者教育、拓寬檢測策略，並在 Alpha-1 社區內合作，識別患有 Alpha-1 的個體。</p>
</div><p><strong>About</strong> <strong>AlphaDetect</strong></p>
<div class="lb-trans"><p><strong>關於 AlphaDetect</strong></p>
</div><p>AlphaDetect, founded in 2025, accelerates detection to uncover everyone genetically at risk for Alpha-1. Located in Durham, NC, AlphaDetect will operate as a limited liability company and a non-profit subsidiary of Alpha-1 Foundation, holding tax-exempt status under Section 501(c) 3 of the Internal Revenue Code.</p>
<div class="lb-trans"><p>AlphaDetect 成立於 2025 年，加速檢測以揭示所有在遺傳上面臨 Alpha-1 風險的人。AlphaDetect 位於北卡羅來納州達勒姆，將作為有限責任公司和 Alpha-1 基金會的非營利子公司運營，享有根據《國內税收法》第 501(c) 3 條款的免税地位。</p>
</div><p>For more information, visit https://alpha1.org/alphadetect/</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 https://alpha1.org/alphadetect/</p>
</div><p>Contact: Cindy Machles</p>
<div class="lb-trans"><p>聯繫人：Cindy Machles</p>
</div><p>cmachles@alphadetect.org</p>
<div class="lb-trans"><p>cmachles@alphadetect.org</p>
</div><p><strong>About Sanofi</strong></p>
<div class="lb-trans"><p><strong>關於賽諾菲</strong></p>
</div><p>Sanofi is an R&amp;D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY</p>
<div class="lb-trans"><p>賽諾菲是一家以研發為驅動、以人工智能為動力的生物製藥公司，致力於改善人們的生活並實現可持續增長。我們運用對免疫系統的深刻理解，發明治療和保護全球數百萬人的藥物和疫苗，擁有一條創新的產品管線，可能使更多人受益。我們的團隊以一個目標為指導：追求科學的奇蹟以改善人們的生活；這激勵我們推動進步，為我們服務的人民和社區帶來積極影響，解決我們時代最緊迫的醫療、環境和社會挑戰。賽諾菲在 EURONEXT: SAN 和 NASDAQ: SNY 上市。</p>
</div><p>For more information, visit www.sanofi.com</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.sanofi.com</p>
</div><p>Contact: Evan Berland</p>
<div class="lb-trans"><p>聯繫人：Evan Berland</p>
</div><p>evan.berland@sanofi.com</p>
<div class="lb-trans"><p>evan.berland@sanofi.com</p>
</div><p><strong>About the Alpha-1 Foundation</strong></p>
<div class="lb-trans"><p><strong>關於 Alpha-1 基金會</strong></p>
</div><p>The Alpha-1 Foundation, founded in 1995, is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by the condition worldwide. A1F has invested over $100 million to support Alpha-1 research and programs at 130 institutions in North America, Europe, the Middle East , and Australia.</p>
<div class="lb-trans"><p>Alpha-1 基金會成立於 1995 年，致力於尋找 Alpha-1 抗胰蛋白酶缺乏症（Alpha-1）的治癒，並改善全球受該疾病影響的人的生活。A1F 已投資超過 1 億美元支持北美、歐洲、中東和澳大利亞 130 個機構的 Alpha-1 研究和項目。</p>
</div><p>For more information, visit alpha1.org</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 alpha1.org</p>
</div><p>Contact: Jeanne Kushner</p>
<div class="lb-trans"><p>聯繫人：Jeanne Kushner</p>
</div><p>jkushner@alpha1.org</p>
<div class="lb-trans"><p>jkushner@alpha1.org</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2973907/Sanofi.jpg" alt="" original-src="https://mma.prnewswire.com/media/2973907/Sanofi.jpg"/></p>
<p>SOURCE Alpha-1 Foundation</p>
<div class="lb-trans"><p>來源：Alpha-1 基金會</p>
</div>

賽諾菲支持 AlphaDetect 以加速 Alpha-1 的檢測 | 賽諾菲股票新聞